... the regenerative period we observed some anatomical abnormalities such as narrowing of the tail tip. These abnormalities were documented in both the control and treatment groups, which indicates that they were unrelated to VEGF induction ( Figure 2 ). [email protected] © The Author(s) 2025. Published by Oxford...

... Model ( https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights ) Abstract Background and Aims Lackluster results from recently completed gene therapy clinical trials of VEGF-A delivered by viral vectors have heightened the need to develop alternative delivery strategies. This study...

...%) received second-line treatments including anti-VEGF therapy or immune checkpoint inhibitor (ICI) and were included in the final analysis. Median OS for all patients was 11.1 months from initiation of second-line therapy. Median OS was 10.7 months (95% CI: 7.2-12.8) and 15.7 months (95%CI: 6.8-NE) for those...

... patients. Expression of vascular endothelial growth factor-C (VEGF-C) and its receptor VEGFR-3 were assessed using qPCR and immunohistochemistry. High-parameter flow cytometry was employed to analyze subsets of CD8+ T cells within the tumors. Results Multivariate analysis revealed that MSI status...

... growth factor (VEGF) on admission were independently associated with a decreased risk of all-cause readmission or death (adjusted hazard ratios [95% confidence intervals], 0.28 [.16–.51] and 0.19 [.08–.48], respectively) and a decreased risk of readmission due to severe malaria (0.27 [.15–.51] and 0.16...

..., activation of β3-AR by mirabegron significantly prevented AngII-induced AD/AA formation in mice. RNA-sequencing analysis of adipocytes from PVAT revealed a notable increase of the lymphangiogenic factor, vascular endothelial growth factor C (VEGF-C), in mirabegron-treated mice. Consistently, enhanced...

... VEGF-TKI Resistance Cabozantinib c-MET Inhibition The Oncologist, 2024, Vol. 29, Supplement 1 S27 Abstract citation ID: oyae181.043 49 Inhibition of AXL along with c-Met potentially halts resistance development in renal cell carcinoma Marc Machaalani MD1, Akash Sabarwal PhD2, Laxminarayan Rawat PhD2...

..., and therapy response in PC. parathyroid carcinoma MEN1 VEGF receptor multi-target tyrosine kinase inhibitors Parathyroid carcinoma (PC) is exceedingly rare, with an annual incidence of 3.5 to 5.7 per 10 million people ( 1 ). Most cases are sporadic, with somatic mutations in genes including...

... of corneal alkali burn in adult rabbits. Corna Alkali burn Exosomes Mesenchymal Stem Cells VEGF TGF-B Histology QJM: An International Journal of Medicine, 2024, Vol. 117, Suppl. 1 | i109 Abstract citation ID: hcae070.250 Effect of Mesenchymal Stem Cells-Derived Exosomes on Healing of a Rabbit Model...

... was successfully inhibited by combined treatment targeting Ang-2 and VEGF. Brain metastases (BM) develop in approximately 20% of all patients suffering from cancer, with the highest incidence in those with lung carcinoma, melanoma, renal, breast, and colorectal carcinoma. ^{1 , 2} Despite continuous...

... ischaemic injury in 12-week high-fat diet fed mice. Additionally, we found that Raptor deficiency dampened vascular endothelial growth factor receptor 2 (VEGFR2) signalling in endothelial cells (ECs) and inhibited VEGF-induced cell migration and tube formation in a PTP1B-dependent manner. Furthermore, mass...

... in the real world was generally consistent with that in clinical studies, and the incidence of TEAEs was numerically lower than known VEGF/VEGFR inhibitor-related AEs. Fruquintinib exhibited manageable safety and tolerability in Chinese patients in the real-world setting. Fruquintinib is approved in China...

...) and provides data to guide sequencing of therapies and patient selection for treatment with tivozanib in the current RCC treatment paradigm. renal cell carcinoma tivozanib tyrosine kinase inhibitor VEGF blockade sequencing MDACC P30 CA016672 Andrew Sabin Family Foundation 10.13039/100012287...

... synovitis outcomes disease activity MMP-3 VEGF Action Medical Research and Humanimal Trust The Albert Gubay Foundation GN 2697 British Society of Rheumatology 179978 Centre of Excellence Centre for Adolescent Rheumatology Versus Arthritis 21593 National Institute...

..., respectively. Furthermore, the ORR and DCR were 36.4% and 72.7%, respectively. The high vascular endothelial growth factor D (VEGF-D) group had a significantly shorter PFS and OS. A combination of high VEGF-A and low VEGF-D levels was associated with a longer PFS. Conclusion Our results showed that RAM...

... to protocol. Next, samples were incubated with anti-HER2 rabbit monoclonal antibody (Abclonal, China)/anti-p53 mouse monoclonal antibody (Abclonal, China)/anti-VEGF rabbit monoclonal antibody (Abclonal, China)for 1 hour at 37°C. After washed 3 times with phosphate buffer saline (PBS), the sections were...

... sample. To circumvent these limitations, we established an induced pluripotent stem cell (iPSC)‐derived model of the melorheostosis. We use this model to show that MAP2K1 mutations result in increased VEGF secretion that, in part, drives increased osteoblast mineralization. Dermal fibroblasts...

..., the anti-tumour activity of ginsenoside Rg3 and doxorubicin by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways. Furthermore, ginsenoside Rg3 combined with doxorubicin inhibits tumour growth and lung metastasis in 143B-derived murine osteosarcoma models. More importantly, ginsenoside Rg3 can...

...Akio Nakane; Shouhei Hirose; Noriaki Kawai; Naoki Fujimoto; Eriko Kondo; Krisana Asano Correspondence: Akio Nakane, [email protected] Present address: Shouhei Hirose: Division of Microbiology, National Institute of Health Sciences, Kawasaki, Japan proteoglycan hair growth VEGF IGF-1R...

...Tao Yang; Guangxu Li; Xifeng Li; Boyang Wei; Hengxian Su; Wenchao Liu; Shenquan Guo; Nan Yang; Tao Xu; Chuanzhi Duan Graphical abstract VEGF Notch graft regeneration remodeling National Natural Science Foundation of China 10.13039/501100001809 81974178 Vascular endothelial growth factor...